ClinicalTrials.gg
Status unknownNCT03439410SMACUpdated Feb 26, 2019

Clinical Complexity in Internal Medicine Wards. San MAtteo Complexity Study

An observational study in Multimorbidity and Health Knowledge, Attitudes, Practice, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Status unknown at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-26.

Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Observational

The sponsor has not verified this record recently (last verified Feb 2019), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Study summary

The progressive rising of multimorbidity, which has been always considered the hallmark of clinical complexity (CC), has made management of the "complex" patient one of the most topical and challenging issues in medicine. However, patient-related factors (multimorbidity, age, frailty, disease severity) pertain only to the biological complexity, while CC is the result of the dynamic interaction between biological complexity and a number of other coexisting factors (socio-economic, cultural, behavioural, environmental). Starting from these premises, the investigators designed a five-year observational prospective longitudinal study that aims to validate and compare a CC score system on a large cohort of patients (n=1000) admitted in internal medicine wards. Clinicians, biostatisticians and epidemiologists will cooperate into the project. A questionnaire that encompasses the main biological and extra-biological factors was designed (Clinical Complexity Index, CCI) by a multiprofessional consensus. This questionnaire will be administered by the investigators to the patients and validated. Consecutive patients will be enrolled every other week for two years and followed-up for 5 years. The primary endpoint will be the validation of the CCI. Thereafter, the investigators will evaluate the correlation between the CCI and the length of stay of the index hospitalization, assuming that a higher CCI score is associated with longer length of stay. The secondary endpoints will be the demonstration of the association between higher CCI score and more health resources utilization (i.e., evaluating occurrence of hospital readmissions, number of accesses to the emergency room, visits at the outpatient clinic, different drugs prescribed and hospital reimbursement according to the local diagnosis-related group [DRG] system) along with worse prognosis (mortality at 1 and 5 years).

Read the detailed description

The Clinical Complexity Index (CCI) that will be validated is made of 25 different variables, divided into 5 domains (biological, socioeconomic, behavioral, environmental, cultural). All variables were dichotomised and were coded -1 (absence of the variable) and +1 (presence of the variable). For each variable, the answer "yes" increases the degree of complexity. See Citations for further details.

Here is the CCI that will be used in the study:

BIOLOGICAL DOMAIN Age > 75 years yes☐ +1 no☐ -1 Intake ≥ 5 medications yes☐ +1 no☐ -1 Cumulative Illness Rating Scale (CIRS) > 3 and/or CIRS severity >3 yes☐ +1 no☐ -1 ↑ frailty (Edmonton Frail Scale > 5) yes☐ +1 no☐ -1

↓ mobilization (Barthel\<60) yes☐ +1 no☐ -1

SOCIO-ECONOMIC DOMAIN Living alone yes☐ +1 no☐ -1 Income \< 1000 €/month yes☐ +1 no☐ -1 Unemployment/precarious work yes☐ +1 no☐ -1 Dependent/disabled family member yes☐ +1 no☐ -1 Need for a caregiver yes☐ +1 no☐ -1

BEHAVIOURAL DOMAIN Inadequate adherence to medications yes☐ +1 no☐ -1 Active smoking of at least 4 cigarettes/day yes☐ +1 no☐ -1 Alcohol (>3 Alcohol Units/day) and/or drug abuse yes☐ +1 no☐ -1 Inappropriate diet yes☐ +1 no☐ -1 Cognitive impairment (Short Blessed Test > 9) yes☐ +1 no☐ -1

ENVIRONMENTAL DOMAIN Institutionalization yes☐ +1 no☐ -1 Difficult access to healthcare yes☐ +1 no☐ -1 Presence of home architectural barriers yes☐ +1 no☐ -1 Occupational exposure to toxins yes☐ +1 no☐ -1 Air pollution yes☐ +1 no☐ -1

CULTURAL DOMAIN Schooling \< 8 years yes☐ +1 no☐ -1 Insufficient access to information yes☐ +1 no☐ -1 Lack of adherence to health screening programs yes☐ +1 no☐ -1 Language barriers yes☐ +1 no☐ -1 Perceived discrimination yes☐ +1 no☐ -1

The investigators will administer the CCI to all patients admitted to the wards (Internal Medicine and Subacute ward), according the study protocol. All the enrolled patients will be followed-up with a phone call after after discharge (at 4-8-12 months) for collecting the following data: occurrence of hospital readmission within 1 month after discharge; the number of readmissions; the number of accesses to the emergency room (ER); the number of visits at the outpatient clinic; the number of different drugs prescribed; mortality. Mortality will also be assessed once a year for 5 years.

02

Conditions studied

  • Multimorbidity
  • Health Knowledge, Attitudes, Practice

Keywords

  • Internal medicine
  • Chronic disease
  • Healthcare expenditure
03

In context

Behavior

1,573 studies on the registry are indexed under Behavior; 313 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 235 across 341 observational studies indexed under Behavior.

Browse Behavior studies →

Lead sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia is the lead sponsor of 257 studies on the registry; 114 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients admitted in the aforementioned wards will be enrolled in the study during the time of the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18
  • Hospitalized in one of the participating Units (Internal Medicine wards or Subacute ward)

Exclusion criteria

Exclusion Criteria:

  • Already enrolled in the study during a previous hospitalization
  • Denied
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Internal Medicine ward

    The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.

    Other: Clinical Complexity Index

  • Subacute ward

    The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.

    Other: Clinical Complexity Index

Interventions

  • OtherClinical Complexity Index

    Clinical Complexity Index (CCI) will be administered at the time of admission to the ward.

06

What researchers measure

Primary outcomes

  1. Validation of the Clinical Complexity Index (CCI)

    Validation of the Clinical Complexity Index (CCI) proposed in the project (see first Citation and Study Description for further details). This index should measure patients' clinical complexity, including biological, socioeconomic, cultural, behavioral, and envirnomental domains. The total score range is -25 to +25 (-5 to +5 per each domain). The investigators expect that a higher value is associated with a worse outcome (higher clinical complexity).

    Time frame: 2 years

Secondary outcomes

  1. Length of stay

    The investigators will measure the length of stay (unit of measurement: days) of each enrolled patient.

    Time frame: 2 years

  2. Healthcare expenditure and utilization

    To demonstrate the association of the Clinical Complexity Index (CCI) with the use of health resources, including the occurrence of hospital readmission within 1 month; the number of readmissions during the first 12 months; the number of accesses to the emergency room (ER) during the first 12 months; the number of visits at the outpatient clinic during the first 12 months; the number of different drugs prescribed during the first 12 months; the hospital reimbursement according to the Regional DRG system for the index hospitalization. Each of these items will be separately analyzed.

    Time frame: 1 year

  3. Mortality

    To evaluate the association between a higher Clinical Complexity Index (CCI) score and mortality at 1 and 5 years.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, Lombardia 27100, Italy
    Recruiting
    • Gino R Corazza, MD · Contactgr.corazza@smatteo.pv.it · 00390382502973
    • Marco V Lenti, MD · Sub investigator
    • Pietro Formagnana, MD · Sub investigator
    • Giampiera Bertolino, MD · Sub investigator
    • Francesco Falaschi, MD · Sub investigator
    • Mariella Ciola, MD · Sub investigator
    • Alice Brera · Sub investigator
    • Gabriele Croce, MD · Sub investigator
    • Franco Barzizza, MD · Sub investigator
    • Elisabetta Pagani, MD · Sub investigator
    • Catherine Klersy, MD · Sub investigator
08

References and documents

Publications

  • Palese A, Brusaferro S. A multidimensional vector model measuring clinical complexity may increase effectiveness in patient assessment. Intern Emerg Med. 2017 Dec;12(8):1287-1289. doi: 10.1007/s11739-017-1722-9. Epub 2017 Aug 4. No abstract available. PubMed 28779449 ↗
  • Corazza GR, Klersy C, Formagnana P, Lenti MV, Padula D; Consensus Panel. A consensus for the development of a vector model to assess clinical complexity. Intern Emerg Med. 2017 Dec;12(8):1313-1318. doi: 10.1007/s11739-017-1709-6. Epub 2017 Jul 14. PubMed 28710713 ↗
  • Lenti MV, Brera AS, Ballesio A, Croce G, Padovini L, Bertolino G, Di Sabatino A, Klersy C, Corazza GR. Resilience is associated with frailty and older age in hospitalised patients. BMC Geriatr. 2022 Jul 10;22(1):569. doi: 10.1186/s12877-022-03251-9. PubMed 35818046 ↗

Individual participant data

Plan to share: Yes — All individual participant data (IPD), anonymized and aggregated, that underlie results in a publication.

Supporting information: Statistical analysis plan, Clinical study report

Time frame: Only on future articles that will be published.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2017 (actual). Primary completion is estimated for Nov 2019, 24 months after the start.

Of 113 non-industry observational studies under Behavior, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 57. This study's planned 24 months is above that.

Counting every sponsor, half of 119 studies reached it within 17 months; a quarter within 6 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2018
First posted
Feb 20, 2018
StartActual
Nov 6, 2017
Primary completionEst.
Nov 6, 2019
CompletionEst.
Nov 6, 2022
Last update
Feb 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03439410
Responsible party
Gino Roberto Corazza (Full Professor of Internal Medicine, Fondazione IRCCS Policlinico San Matteo di Pavia) — Principal investigator
First posted
Feb 20, 2018
Start date
Nov 6, 2017
Primary completion
Nov 6, 2019 (estimated)
Completion
Nov 6, 2022 (estimated)
Last update
Feb 26, 2019

Study contacts

Gino R Corazza, MD
Contact
gr.corazza@smatteo.pv.it
00390382502973
Gino R Corazza, MD
principal investigator · Fondazione IRCCS Policlinico San Matteo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion